Webcast scheduled for Monday, April 27, 2026 at 8:00am ET.BOSTON, April 24, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), ...

Have you ever wished to drive microscopic matter along an arbitrarily tailored trajectory instead of just a circle? That's ...

Scientists have unveiled a breakthrough imaging method that can capture the hidden details of events unfolding in trillionths ...

The Phase II trial enrolled 129 participants, of whom 94% had relapsing remitting multiple sclerosis, and 6% had secondary ...

Addex spin-out company Neurosterix on track to complete phase 1 study of NTX-253 for schizophrenia in Q2 2026: Geneva, Switzerland Saturday, April 25, 2026, 14:00 Hrs [IST] Addex ...

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 23, 2026-Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage ...

Satralizumab is safe and effective for patients with myelin oligodendrocyte glycoprotein antibody-associated disease, the new ...

While the primary motor endpoint showed modest improvement, more notable effects were observed in non-motor domains.

Oral MYC condensate modulator drives tumor regression and stasis in preclinical modelsDisruption of MYC condensates enables ...

Harmony Biosciences is a profitable, single-asset company built on Wakix. Click here to read why HRMY stock is a Sell.

Expands potential opportunities for AKTX-101 and its novel RNA splicing modulator payload in additional tumors beyond current ...